REDEFINE 1 (NCT05567796), REDEFINE 2 (NCT05394519), REDEFINE 3 (NCT05669755), REDEFINE 4 (NCT06131437), REDEFINE 11 (NCT07011667), REIMAGINE 2 (NCT06065540)
semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
p 90% on RAASi and -blockers, and 70% on MRA), and 50% of participants had T2D
Available in soft pack only
Eternal Peptides provides a lot-specific Certificate of Analysis for every GLOW Blend lot
Studies on animals have shown potential risks to fetal development, and there is limited human data to confirm their safety